Search results

Filters
Close
ADDED DATE
Added date
TOPICS Please select
WATCH / LISTEN / READ TIME
AHA 25: The POLY-HF Trial
Author(s): Ambarish Pandey Added: 4 days ago
AHA Scientific Sessions 2025 – Dr Ambarish Pandey (University of Texas Southwestern Medical Center, US) presents results from the POLY-HF trial (NCT04633005), evaluating a polypill strategy combining multiple evidence-based medications for heart failure with reduced ejection fraction.This single-center randomized trial enrolled 212 patients with HFrEF (ejection fraction ≤40%) who were not… View more

Heart Failure
ESC/EACTS Guidelines 2025 for VHD Address Patient Values
Author(s): Benoit Mores Added: 1 week ago

Anticoagulation
AHA 25: The PFA-SHAM Study
Author(s): Vivek Reddy Added: 3 days ago
AHA 2025 - Dr Vivek Y Reddy (Icahn School of Medicine at Mount Sinai, New York, US) joins us to share findings from the PFA-SHAM study (NCT05717725) investigating pulsed field ablation (PFA) versus sham ablation to treat AF. Patients enrolled in the study underwent an electrophysiology study to ensure they had no concealed AV bypass tract or supraventricular tachycardia, and patients were then… View more

Electrophysiology & Arrhythmia
ESC 25: SWEDEPAD 1 and 2
Author(s): Marten Falkenberg , Joakim Nordanstig Added: 2 months ago
ESC Congress 2025 - Paclitaxel-coated devices in critical limb threatening ischemia were not effective in preventing amputation, nor improving quality-of-life in intermittent claudication.Dr Mårten Falkenberg (Sahlgrenska University Hospital, Gothenburg, SE) and Prof Joakim Nordanstig (Sahlgrenska University Hospital, Gothenburg, SE) join us to discuss findings from the SWEDEPAD 1 and 2 parallel… View more

Intervention

Vascular Disease and Surgery
AHA 25: The FOOD-HF Trial
Author(s): Ambarish Pandey Added: 4 days ago
AHA Scientific Sessions 2025 – Dr Ambarish Pandey (University of Texas Southwestern Medical Center, US) presents findings from a randomized clinical trial comparing medically tailored meals versus produce supplements on heart failure readmissions and emergency department visits.The study was conducted across two centers in Dallas, Texas. Patients were randomized within two weeks following heart… View more

Heart Failure

Prevention & Chronic Conditions
AHA 25: The DARE-AF Trial
Author(s): Chao Jiang , Zhao Zixu Added: 5 days ago
AHA Scientific Sessions 2025 – Dr Chao Jiang and Dr Zhao Zixu (Beijing Anzhen Hospital, CN) discuss the findings from the DARE-AF (NCT06433479) randomized clinical trial, investigating whether dapagliflozin reduces atrial fibrillation burden following catheter ablation in patients without diabetes or heart failure.This single-center, open-label trial enrolled 200 patients with persistent atrial… View more

Electrophysiology & Arrhythmia
ACC 25 Late-Breaking Discussion: The STRIDE Trial
Author(s): Harriette Van Spall , Marc P Bonaca Added: 7 months ago
ACC 25 - STRIDE shows subcutaneous semaglutide improved walking ability and related quality of life in patients with both type 2 diabetes and peripheral arterial disease (PAD) with intermittent claudication symptoms.Late-Breaker host, Dr Harriette Van Spall (McMaster University, Hamilton, CA) is joined by Dr Marc Bonaca (University of Colorado School of Medicine, Aurora, CO, US) to discuss the… View more

Vascular Disease and Surgery

Prevention & Chronic Conditions
ESC 24: SHAM-PVI: Sham Study of Pulmonary Vein Isolation in Symptomatic Atrial Fibrillation
Author(s): Rick Veasey Added: 1 year ago
ESC Congress 24 — SHAM-PVI study finds pulmonary vein isolation effective in reducing atrial fibrillation (AF) episodes, improving quality of life.We are joined onsite by Dr Rick Veasey (Eastbourne District General Hospital, Eastbourne, UK) to discuss the findings from a SHAM-PVI, a randomized sham-controlled study of pulmonary vein isolation in symptomatic atrial fibrillation (NCT04272762; East… View more

Electrophysiology & Arrhythmia
ESC 25: TRISCEND II Trial: TTVR Outcomes by Baseline TR Severity
Author(s): Philipp Lurz Added: 2 months ago
ESC Congress 2025 - New findings from a post-hoc analysis of TRISCEND II show that TTVR can reduce the rate of heart failure hospitalisations, particularly in the case of patients who present with massive or torrential TR - irrespective of baseline TR severity.Prof Philipp Lurz (University Mainz, DE) discusses new findings from the TRISCEND II trial, examining how baseline tricuspid regurgitation… View more

Intervention